EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

HCM Risk-SCD score and its relation with functional status and comorbidities in HCM patients

Barbara Krywult, Jakub Kromołowski, Maria Kaspera, Zuzanna Niedoba, Karolina Nogala, Julia Nowak, Maciej Podolski, Katarzyna Mizia-Stec

Annales Academiae Medicae Silesiensis · 16.11.2026

DOI: 10.18794/aams/242511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annales Academiae Medicae Silesiensis, online erschienen am 16.11.2026. Verfasst von Barbara Krywult und 7 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder associated with heart failure, arrhythmias, and an increased risk of sudden cardiac death (SCD). Functional status and the HCM Risk-SCD score are key parameters guiding management. This study assessed the relationship between functional status, comorbidity burden, and the HCM Risk-SCD score in patients with HCM. Material and methods This retrospective single-cohort study included 56 patients with HCM. The HCM Risk-SCD score was calculated according to the 2023 ESC guidelines. Patients were stratified by heart failure symptoms into asymptomatic (NYHA I) and symptomatic (NYHA II–III) groups, and by comorbidity burden into low (0–1) and high (≥2) groups. Assessed comorbidities included systemic hypertension, hyperlipidemia, coronary artery disease, chronic kidney disease, COPD, and type 2 diabetes.

Results

The median HCM Risk-SCD score was higher in asymptomatic than symptomatic patients (3.46% [IQR 2.38-4.44] vs. 2.07% [IQR 1.17-2.23]; p=0.005). No significant difference was observed between patients with low and high comorbidity burden (1.95% vs. 2.01%; p=0.765), and no correlation was found between the HCM Risk-SCD score and the number of comorbidities (rho=-0.07, p=0.607).

Conclusions

Asymptomatic patients with HCM had a higher estimated risk of SCD than symptomatic patients. The HCM Risk-SCD score appeared to be independent of comorbidity burden. This shows that HCM individuals with better clinical and functional status may be at higher risk of SCD.

Zitieren

APA

Krywult, B., Kromołowski, J., Kaspera, M., Niedoba, Z., Nogala, K., Nowak, J., Podolski, M., & Mizia-Stec, K. (2026). HCM Risk-SCD score and its relation with functional status and comorbidities in HCM patients. Annales Academiae Medicae Silesiensis. https://doi.org/10.18794/aams/242511

Vancouver

Krywult B, Kromołowski J, Kaspera M, Niedoba Z, Nogala K, Nowak J, et al. HCM Risk-SCD score and its relation with functional status and comorbidities in HCM patients. Annales Academiae Medicae Silesiensis. 2026. doi:10.18794/aams/242511

BibTeX
@article{Krywult2026,
  author = {Krywult, Barbara and Kromołowski, Jakub and Kaspera, Maria and Niedoba, Zuzanna and Nogala, Karolina and Nowak, Julia and Podolski, Maciej and Mizia-Stec, Katarzyna},
  title = {HCM Risk-SCD score and its relation with functional status and comorbidities in HCM patients},
  journal = {Annales Academiae Medicae Silesiensis},
  year = {2026},
  doi = {10.18794/aams/242511}
}
Kostenlos starten →